- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Progesterone receptor is a significant factor associated...
Open Collections
UBC Faculty Research and Publications
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients Liu, Shuzhen; Chia, Stephen; Mehl, Erika; Leung, Samuel; Cheang, Maggie Chong U.; Nielsen, Torsten
Abstract
Purpose: Estrogen receptor status in breast cancer is associated with response to hormonal therapy and clinical outcome. The additional value of progesterone receptor (PR) has remained controversial. We examine the value of PR for prognosis and response to tamoxifen on a population-based series of 4,046 invasive early stage breast cancer patients. Methods: Clinical information for age at diagnosis, stage, pathology, treatment and outcome was assembled for the study cohort; the median follow-up was 12.4 years. PR status was determined by immunohistochemistry using a rabbit monoclonal antibody on tissue microarrays built from breast tumor surgical excisions. Survival analyses, Kaplan-Meier functions and Cox proportional hazards regression models were applied to assess the associations between PR and breast cancer specific survival. Results: Progesterone receptor was positive in 51% of all cases and 67% of estrogen receptor positive (ER+) cases. Survival analyses for both the whole cohort and ER+ cases given tamoxifen therapy showed that patients with PR+ tumors had 24% higher relative probability for breast cancer specific survival as compared to PR- patients, adjusted for ER, HER2, age at diagnosis, grade, tumor size, lymph node status and lymphovascular invasion covariates. Higher PR expression showed stronger association with patient survival. Log-likelihood ratio tests of multivariate Cox proportional hazards regression models demonstrated that PR was an independent statistically significant factor for breast cancer specific survival in both the whole cohort and among ER+ cases treated with tamoxifen. Conclusion: PR adds significant prognostic value in breast cancer beyond that obtained with estrogen receptor alone.
Item Metadata
Title |
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients
|
Creator | |
Contributor | |
Publisher |
Springer
|
Date Issued |
2009-02-10
|
Description |
Purpose: Estrogen receptor status in breast cancer is associated with response to hormonal
therapy and clinical outcome. The additional value of progesterone receptor (PR) has remained
controversial. We examine the value of PR for prognosis and response to tamoxifen on a
population-based series of 4,046 invasive early stage breast cancer patients.
Methods: Clinical information for age at diagnosis, stage, pathology, treatment and outcome
was assembled for the study cohort; the median follow-up was 12.4 years. PR status was
determined by immunohistochemistry using a rabbit monoclonal antibody on tissue microarrays
built from breast tumor surgical excisions. Survival analyses, Kaplan-Meier functions and Cox
proportional hazards regression models were applied to assess the associations between PR and
breast cancer specific survival.
Results: Progesterone receptor was positive in 51% of all cases and 67% of estrogen receptor
positive (ER+) cases. Survival analyses for both the whole cohort and ER+ cases given
tamoxifen therapy showed that patients with PR+ tumors had 24% higher relative probability for
breast cancer specific survival as compared to PR- patients, adjusted for ER, HER2, age at
diagnosis, grade, tumor size, lymph node status and lymphovascular invasion covariates. Higher
PR expression showed stronger association with patient survival. Log-likelihood ratio tests of
multivariate Cox proportional hazards regression models demonstrated that PR was an
independent statistically significant factor for breast cancer specific survival in both the whole
cohort and among ER+ cases treated with tamoxifen.
Conclusion: PR adds significant prognostic value in breast cancer beyond that obtained with
estrogen receptor alone.
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2021-06-15
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution-NonCommercial-NoDerivatives 4.0 International
|
DOI |
10.14288/1.0398418
|
URI | |
Affiliation | |
Citation |
Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010 Jan;119(1):53-61.
|
Publisher DOI |
10.1007/s10549-009-0318-0
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty; Researcher; Graduate
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International